sub:assertion {
d:DB05708 v:identifier "DB05708" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB05708" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB05708> ;
dv:drugbank-id "DB05708" ;
dv:x-cas <
http://bio2rdf.org/cas:156223-05-1> ;
dv:x-chemspider <
http://bio2rdf.org/chemspider:4942844> ;
dv:x-pubchemcompound <
http://bio2rdf.org/pubchem.compound:6438361> ;
dv:x-pubchemsubstance <
http://bio2rdf.org/pubchem.substance:43031369> ;
dct:description "GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006. GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention related and memory related tasks (Kitagawa, et al. Neuropsychopharmacology (2003), 28, 542-551)."@en ;
dct:identifier "drugbank:DB05708" ;
dct:title "GTS-21"@en ;
a dv:Drug ;
rdfs:label "GTS-21 [drugbank:DB05708]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB05708> .
}